Designer Babies: Human cloning is a long way off, but bioengineered kids are already here.
By Shannon Brownlee,
The Washington Monthly
| 02. 28. 2002
In the mid-1990s, embryologist Jacques Cohen pioneered a promising
new technique for helping infertile women have children. His
technique, known as cytoplasmic transfer, was intended to "rescue"
the eggs of infertile women who had undergone repeated, unsuccessful
attempts at in vitro fertilization, or IVF. It involved injecting
the cytoplasm found inside the eggs of a fertile donor, into
the patient's eggs.
When the first baby conceived through cytoplasmic transfer was
born in 1997, the press instantly hailed Cohen's technique as
yet another technological miracle. But four years later, the
real story has proven somewhat more complicated. Last year,
Cohen and his colleagues at the Institute for Reproductive Medicine
and Science of St. Barnabas, a New Jersey fertility clinic,
set off alarm bells among bioethicists with the publication
of a paper detailing the genetic condition of two the 17 cytoplasmic-transfer
babies born through the clinic to date. The embryologists reported
that they had endowed the children with extra bits of a special
type of genetic material, known as mitochondrial DNA, or mtDNA,
which came with the cytoplasm transferred from the donor...
Related Articles
By David Jensen, The California Stem Cell Report | 03.26.2026
SACRAMENTO, Ca. -- California’s $12 billion stem cell and gene therapy program scored a historic first today, announcing that it had for the first time helped to finance a revolutionary treatment that will now be available to the general public...
Cathy Tie seems to be good at starting businesses but not so dedicated to maintaining them. CGS, like many others, first heard of her thanks to Caiwei Chen and Antonio Regalado in MIT Technology Review, May 2025, as the partner (perhaps bride) of the notorious Chinese scientist He Jiankui, described in the headline as “China’s Frankenstein.” He prefers “Chinese Darwin.” She ran his Twitter account for a while, contributing such gems as:
Get in luddite, we’re going gene editing...
By Laura DeFrancesco, Nature Biotechnology | 03.17.2026
The first gene editors designed to fix genetic lesions in mutation-agnostic ways are poised to enter the clinic. Tessera Therapeutics and Alltrna, two Flagship Pioneering-funded companies, are gearing up to test novel genetic medicines in humans. Tessera received regulatory clearance...
By Darren Incorvaia, Fierce Biotech | 03.11.2026
A new method for safely inserting large chunks of DNA into genomes has now measured up in mice, potentially paving the way for the next generation of gene editing medicines.
The approach, which is described in a Nature paper...